Ann Arbor’s Phenomics Health Inc., a bioinformatics platform-based precision medicine company, today announced it has acquired the patented pharmacometabolomic technology portfolio of Precera Bioscience, based in Franklin, Tenn. (south of Nashville).
Phenomics Health plans to integrate the new technology with its own patented, advanced pharmacogenomics platform to offer healthcare providers a more complete view of patients’ potential and actual response to medications than is currently available.
To be marketed under the PrecīsMed brand and licensed to clinical laboratories and healthcare systems, the patented pharmacometabolomic technology enables detection, quantitative measurement, and comprehensive assessment of more than 200 medications in a patient’s bloodstream.
Combined with Phenomics Health’s technology, the resulting information from PrecīsMed will help clinicians personalize drug therapy by determining what medications and doses a patient is actually taking (whether prescribed or not), drug-drug interactions, and how genetics may impact the body’s ability to process those medications.
“This is the first time that both advanced pharmacogenomics and pharmacometabolomics platforms have come together under one roof,” says Dr. James S. Burns, co-founder, chairman and president, of Phenomics Health. “PrecīsMed could help improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs – the real definition of precision medicine.”
Studies have found that 33 percent of medications taken by patients are not in their medical record, and approximately half of prescribed medications are not taken at all. In addition, about 55 percent of medications are taken at levels outside of their prescribed range while another 50 percent experience significant drug interaction alerts arising from unknown medications.
“Poor adherence to medication leads to increased morbidity and death and is estimated to incur costs of approximately $100 billion per year,” according to a report published in the Mayo Clinic Proceedings.
Patients who suffer from comorbid disorders often require treatments with multiple medications, which can result in missed, wrong, or multiple dosages. Additionally, genetics can play a role in determining whether a medication is as effective as it could or should be, as well as disease state, drug-drug interactions, and socio-cultural or environmental conditions.
Clinical studies published in 2018 have demonstrated that PrecīsMed, which obtains a patient’s blood sample with a finger stick, can accurately assess prescribing trends, medication adherence and electronic health record (EHR) coverage, as well as define medication concentrations in patients with comorbid disorders.
Phenomics Health also plans to use the information gathered from de-identified patient population data to inform its machine learning and AI-based bioinformatics platform, which can be mined for present and future research.